Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Mylan Inc. Stories

2013-09-04 12:33:15

- Investment expected to generate more than 160 new jobs and supports company's ongoing growth in core product technology- ST. ALBANS, Vt., Sept. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the completion of an 85,000 square foot, three-story expansion project at its transdermal patch facility, operated by Mylan Technologies Inc. (MTI), in St. Albans, Vt. Through Mylan's investment, including funding for expanded research and development (R&D)...

2013-09-03 12:27:06

PITTSBURGH, Sept. 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its proposed acquisition of the Agila injectables businesses from Strides Arcolab Limited (BSE: 532531, NSE: STAR) has received approval from India's Foreign Investment Promotion Board (FIPB). Subsequently, the transaction also received approval from the Cabinet Committee on Economic Affairs (CCEA). The transaction is expected to close in the fourth quarter of 2013, subject to remaining regulatory...

2013-08-22 12:28:16

-Company continues to supply product to U.S. market - PITTSBURGH, Aug. 22, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) providing bioequivalence study results requested by FDA for Bupropion Hydrochloride (HCl) Extended-release (ER) Tablets USP (XL), 300 mg. Bupropion HCl ER Tablets USP (XL) are the generic...

2013-08-14 08:29:14

This Back-to-School Season, Mylan Specialty L.P. Encourages People to be Better Prepared for a Life-Threatening Allergic Reaction BASKING RIDGE, N.J., Aug. 14, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced it is continuing the EpiPen4Schools(TM) program. In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr(®)...

2013-08-07 08:29:08

Editor Note: For more information about this release, please scroll to bottom NEW YORK, August 7, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Mylan Inc. (NASDAQ: MYL), ImmunoGen, Inc. (NASDAQ: IMGN), Emeritus Corporation (NYSE: ESC), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-08-01 08:34:10

Reaffirms 2013 Adjusted Diluted EPS Guidance Range of $2.75 - $2.95 PITTSBURGH, Aug. 1, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and six months ended June 30, 2013. Financial Highlights Adjusted diluted EPS of $0.68 for the three months ended June 30, 2013 compared to $0.60 for the same prior year period, an increase of 13% Total revenues of $1.70 billion for the three months ended June 30, 2013 compared to $1.69 billion...

2013-07-26 12:25:31

PITTSBURGH, July 26, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. Court of Appeals for the Federal Circuit has reversed a district court's finding related to Teva's U.S. Patent 5,800,808 for Copaxone®, thereby invalidating the patent. Mylan CEO Heather Bresch said, "We are very pleased with today's ruling and we expect that it will allow Mylan to launch its generic version of Copaxone® on May 25, 2014 upon expiration of Teva's Orange Book patents,...

2013-07-26 08:25:16

-Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, July 26, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by Eisai Co., Ltd., Eisai Inc., and Novartis Pharma AG in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Rufinamide Tablets, 200 mg and 400 mg. This product is the generic version of BANZEL(®), which is indicated for the...

2013-07-24 12:28:37

LONDON, July 24, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Tuesday, July 23, 2013, shares in healthcare companies ended on a mixed note, tracking the broader market. The major movers in the sector included Johnson & Johnson (NYSE: JNJ), Mylan Inc. (NASDAQ: MYL), Array Biopharma Inc. (NASDAQ: ARRY), and Brookdale Senior Living Inc. (NYSE: BKD). AAAResearchReports.com has released full comprehensive research...

2013-07-24 08:29:48

PITTSBURGH, July 24, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg. This product is the generic version of TARCEVA(®), and is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or...